1-Heterocyclylalkyl-3-sulfonylindole or -indazole derivatives as 5-hydroxytryptamine-6 ligands
申请人:Bernotas Charles Ronald
公开号:US20060030593A1
公开(公告)日:2006-02-09
The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.
本发明提供了一种I式化合物及其用途,用于治疗与5-HT6受体相关或受其影响的中枢神经系统疾病。
1-HETEROCYCLYLALKYL-3-SULFONYLINDOLE OR -INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
申请人:Wyeth
公开号:EP1554244A1
公开(公告)日:2005-07-20
US6995176B2
申请人:——
公开号:US6995176B2
公开(公告)日:2006-02-07
US7589108B2
申请人:——
公开号:US7589108B2
公开(公告)日:2009-09-15
[EN] 1-HETEROCYCLYLALKYL-3-SULFONYLINDOLE OR -INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS<br/>[FR] LIGANDS DE LA 5-HYDROXYTRYPTAMINE-6 A BASE DE DERIVES DE 1-HETEROCYCLYLALKYL-3-SULFONYL-INDOLE OU -INDAZOLE
申请人:WYETH CORP
公开号:WO2004009548A1
公开(公告)日:2004-01-29
The present invention provides a compound of formula (I) and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.